Cargando…
Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?
INTRODUCTION: In metastatic renal cell carcinoma (mRCC), the bone is the second most common site of metastasis and is associated with increased morbidity and poorer quality of life. Bone-targeted therapies (BTTs) such as denosumab and zoledronic acid may prevent skeletal-related events (SREs). Howev...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931200/ https://www.ncbi.nlm.nih.gov/pubmed/31869748 http://dx.doi.org/10.1016/j.tranon.2019.10.009 |